Pages that link to "Q43991035"

The following pages link to Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection (Q43991035):

Displaying 26 items.

• Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors (Q34556386) (← links)
• Micellar electrokinetic chromatographic determination of rosuvastatin in rabbit plasma and evaluation of its pharmacokinetics and interaction with niacin. (Q35168596) (← links)
• Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers (Q35804141) (← links)
• The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive (Q35825998) (← links)
• No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin (Q37399440) (← links)
• Validated high-performance liquid chromatographic method for the estimation of rosuvastatin calcium in bulk and pharmaceutical formulations (Q39532392) (← links)
• Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia (Q40521213) (← links)
• Development and Validation of a Stability-Indicating RP-UPLC Method for Determination of Rosuvastatin and Related Substances in Pharmaceutical Dosage Form (Q41837927) (← links)
• Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects (Q41871830) (← links)
• Simultaneous determination of rosuvastatin and amlodipine in human plasma using tandem mass spectrometry: Application to disposition kinetics (Q41968437) (← links)
• Development, validation of liquid chromatography-tandem mass spectrometry method for simultaneous determination of rosuvastatin and metformin in human plasma and its application to a pharmacokinetic study (Q41984694) (← links)
• Automated liquid-liquid extraction method for high-throughput analysis of rosuvastatin in human EDTA K2 plasma by LC-MS/MS. (Q42807207) (← links)
• Determination of rosuvastatin in urine by spectrofluorimetry after liquid-liquid extraction and derivatization in acidic medium (Q43482835) (← links)
• No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers (Q44237130) (← links)
• Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment (Q44334631) (← links)
• The effect of erythromycin on the pharmacokinetics of rosuvastatin (Q44395020) (← links)
• An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers (Q44442585) (← links)
• A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers (Q44598069) (← links)
• Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers (Q44704645) (← links)
• ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. (Q45993642) (← links)
• Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics (Q46607005) (← links)
• A simple assay for the simultaneous determination of rosuvastatin acid, rosuvastatin-5S-lactone, and N-desmethyl rosuvastatin in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS). (Q47247595) (← links)
• Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. (Q53568394) (← links)
• Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects. (Q54006194) (← links)
• Microdosing Cocktail Assay Development for Drug-Drug Interaction Studies (Q88084113) (← links)
• Hydrophilic Interaction Liquid Chromatography-Electrospray Ionization Mass Spectrometry for Therapeutic Drug Monitoring of Metformin and Rosuvastatin in Human Plasma (Q89314552) (← links)